A comprehensive view of Galecto, Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Galecto completes enrollment for Phase 2b trial of inhaled GB0139 galectin-3 inhibitor for idiopathic pulmonary fibrosis delivered by generic dry powder inhaler; about 100,000 patients in US affected by IPF

Galecto's Phase 2 trial shows inhaled galectin-3 inhibitor GB0139 prevents escalation of viral-induced inflammatory response, acute and chronic fibrosis in COVID-19 patients requiring oxygen; drug administered in 20mg, 10mg doses

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count